Cette étude a été menée dans le cadre du projet du consortium ODIN « Renforcer la surveillance environnementale pour faire progresser les actions de santé publique », soutenu par la ...
This study was conducted under the ODIN consortium project “Strengthening Environmental Surveillance to Advance Public Health Action”, supported by the European Commission through Horizon Europe (Grant Agreement No. 101103253) and ...
Tarja Pitkänen Introduction La professeure Tarja Pitkänen occupe le poste de chercheuse principale au sein du projet ODIN, apportant au consortium plusieurs décennies d'expérience dans les domaines de la santé ...
Tarja Pitkänen Introduction Professor Tarja Pitkänen serves as a Principal Investigator within the ODIN project, bringing decades of experience in environmental health and water microbiology to the consortium. She serves ...
Marc Christian Tahita Introduction Le Dr Marc Christian Tahita est un chercheur clinique senior et spécialiste en santé publique basé au Burkina Faso. Il possède une vaste expérience dans les ...
The BSI will help facilitate the timely and ethical collection of biological samples in an outbreak. The BSI aims to make biospecimens available to develop assays and standards within weeks, rather than the six months it typically takes today. Read more
CEPI has published its first Biosecurity Policy, strengthening safe, responsible, and equitable research. The Policy outlines clear biosecurity and biosafety requirements for Third Parties, supporting our mission to advance global health preparedness and protect communities through secure scientific innovation. Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
It aims to guide researchers, funders, and policymakers in aligning ongoing and future studies with the most pressing policy needs. The agenda also aims to strengthen coordination and ensure that new evidence directly informs national and regional vaccine readiness decisions. Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
On Sept 8, 2025, West African Ministers of Health pledged their joint commitment to advance development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant regional health security threat posed by the disease Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
